Sherry Aulin Sells 18,709 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $38.63 on Friday. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -13.70 and a beta of 1.19. The company has a 50 day moving average of $41.85 and a 200-day moving average of $40.46. Xenon Pharmaceuticals Inc. has a one year low of $35.53 and a one year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the business earned ($0.73) earnings per share. Equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Institutional Trading of Xenon Pharmaceuticals

A number of large investors have recently made changes to their positions in XENE. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Xenon Pharmaceuticals by 1.1% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 421,121 shares of the biopharmaceutical company’s stock valued at $16,419,000 after buying an additional 4,385 shares during the period. Fiera Capital Corp lifted its position in shares of Xenon Pharmaceuticals by 1.1% in the second quarter. Fiera Capital Corp now owns 582,879 shares of the biopharmaceutical company’s stock worth $22,726,000 after purchasing an additional 6,337 shares in the last quarter. Arizona State Retirement System lifted its position in Xenon Pharmaceuticals by 4.0% during the 2nd quarter. Arizona State Retirement System now owns 17,949 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 688 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Xenon Pharmaceuticals by 1.6% during the second quarter. Envestnet Asset Management Inc. now owns 48,946 shares of the biopharmaceutical company’s stock valued at $1,908,000 after purchasing an additional 769 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Xenon Pharmaceuticals by 6.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 436,460 shares of the biopharmaceutical company’s stock worth $17,011,000 after purchasing an additional 26,253 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Raymond James restated an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Finally, William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $56.00.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.